Philips says it has completed actionable registrations across sleep therapy and ventilator devices and is closing the U.S. Patient Portal related to its recall as of Jan. 1, 2026.

In a key post-recall milestone, Philips says it has more than doubled its number of 510(k) clearances from the U.S. Food and Drug Administration (FDA) over the past two years.

ResMed (NYSE:RMD) is seeing growing use of wearable devices for sleep apnea pre screening, widening its reach before patients ever enter a sleep lab. Recent FDA approvals are supporting ResMed's role ...

PITTSBURGH — A Pennsylvania federal court remanded a California woman’s negligence complaint over injuries allegedly caused by a recalled Philips CPAP device back to Los Angeles County Superior Court.

A rival re-emerges, investors brace for impact and the Ozempic scare dissolves. ResMed’s growth story just got more interesting. ... Read More The post Dr Boreham’s Crucible: A rival may be circling, ...